The Psoriasis and Psoriatic Arthritis Center of NYU Medical Center offers a comprehensive approach to the treatment people suffering from psoriasis. Because as many as one-third of all people with moderate to severe psoriasis also have debilitating and permanently destructive joint disease (psoriatic arthritis), the Center addresses each patient from both a dermatologic and rheumatologic point of view. In fact, each patient is followed in the same centralized location by both a dermatologist (for the skin disease), and a rheumatologist (for the joint disease).
A comprehensive approach allows us to use both topical and systemic medications tailored to the needs of each specific patient. We specialize in traditional medications such as methotrexate and cyclosporine, but also the newer biologic medications such as alefacept (Amevive), etanercept (Enbrel), and infliximab (Remicade and (Raptiva) We also offer ultraviolet phototherapy (PUVA and UVB). Finally, eligible patients are always informed of and offered enrollment in the current clinical trials at NYU Medical Center and at the Hospital for Joint Diseases that address the problems of psoriasis and psoriatic arthritis.